Drug Pipeline Insights Report
4 new drugs to watch this year
Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: Jan. 2023
Slowing Alzheimer's decline and a potential cure for hemophilia A
Welcome to the first issue of Drugs to Watch for 2023
In this Drug Pipeline Insights Report, we feature:
- Two new treatments for Alzheimer's disease: lecanemab and donanemab
- RoctavianTM (valoctocogene roxaparvovec), a first-in-class gene therapy for hemophilia A
- A first-in-class, non-hormonal treatment for menopause associated-vasomotor symptoms (VMS): fezolinetant
New hope for hemophilia
Roctavian could reduce or eliminate the need for costly clotting factor replacement therapy in some patients. Last fall, we reviewed etranacogene dezaparvovec for hemophilia B, which is now approved with the brand name Hemgenix®
Don't want to read the full report? Download the brief summary.
Related content
3 new drugs to watch this fall
As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.
4 key forces shaping the future of pharmacy
These emerging trends will help define the road ahead.
Fighting Fraud in Pharmacy
Explore emerging trends and strategies to combat schemes.
Top